|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rating Action: Moody's to withdraw Alere's ratings following debt redemption. Global Credit Research- 05 Oct 2017. New York, October 05, 2017-- Moody's Investors Service will withdraw Alere Inc.' s ratings ...
NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Alere Inc. (ALR) Lifshitz & Miller announces that on August 23, 2017 , the U.S. District Court for the District of Massachusetts denied ALR's motion to dismiss a ...
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories' (ABT) acquisition of Alere (ALR).
Short interest is low for ALR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding ALR are favorable, with net inflows of $2.40 billion.
LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alere Inc. (NYSE: ALR ), following which we have published a free ...
WALTHAM, Mass., Oct. 2, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, today announced that its Alere™ i Influenza A & B 2 test has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the detection of influenza A and B infection in children and adults. Alere i Influenza A & B 2 is a second-generation rapid molecular assay, which delivers lab accurate results in less time, with the ability to report a positive result in as little as 5 minutes. Alere i Influenza A & B 2 also offers increased sample flexibility with nasopharyngeal swabs now validated for direct use, as well as, in transport media.
WALTHAM, Mass. , Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced the U.S. Department of Justice (the "DOJ") ...
WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (ALR) announced today that Abbott's acquisition of Alere is intended to close on October 3, 2017. Alere intends to request that the New York Stock Exchange cease trading of Alere's common stock before market open on October 3, 2017. Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™.
WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached an agreement in principle to settle with the U.S. Department of Justice (the "DOJ") to resolve various potential civil claims, including claims under the False Claims Act, relating to Alere Triage® cardiac and Toxicology products sold between January 2006 and March 31, 2012. The settlement relates to matters arising out of the previously disclosed 2012 FDA inspection of Alere San Diego and the Office of Inspector General subpoena.
Abbott Laboratories has won U.S. antitrust approval to buy Alere Inc on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday. Alere's shares were up 3.5 percent at $50.61 in mid-afternoon trading on Thursday while Abbott was up 3 percent at $53.72. Abbott first offered to buy Alere in February 2016, but the deal ran into trouble because of issues related to the diagnostic maker's accounting and sales practices.
Alere Inc has agreed to pay more than $13 million to resolve charges the diagnostic testing firm committed accounting fraud and made improper payments to foreign officials, the U.S. Securities and Exchange Commission said on Thursday. The settlement with Alere resolved an investigation that began in 2015 before Abbott Laboratories agreed to buy the Waltham, Massachusetts-based company in a $5.3 billion deal expected to close later this year.
WALTHAM, Mass. , Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached a settlement with the United ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alere, Inc. a score of 6. Our analysis is based on comparing Alere, Inc. with the following peers – Quidel Corporation, Bio-Rad Laboratories, Inc. Class A, Abbott Laboratories, Chembio Diagnostics, Inc., Danaher Corporation, Procter & Gamble Company, Hill-Rom Holdings, Inc., OraSure Technologies, Inc., Meridian Bioscience, Inc. and ... Read more (Read more...)
WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (ALR) ("Alere"), today announced that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention to voluntarily delist its Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the "Preferred Stock"), from the NYSE. The voluntary delisting is subject to and conditioned upon the completion of its acquisition by Abbott Laboratories, an Illinois corporation ("Abbott"). Abbott has informed Alere that it intends to consummate its offer to purchase all outstanding shares of the Preferred Stock (the "Offer") following the completion of the acquisition of Alere and upon satisfaction of all other conditions to the Offer, and thereafter to cancel all remaining shares of Preferred Stock in exchange for the liquidation preference, plus accrued but unpaid dividends, due on such shares of Preferred Stock.
WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE:ALR-B). Such payment will cover the amount of all dividends accrued from July 1, 2017 through September 30, 2017. Abbott Laboratories has made an offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock at $402.00 per share, plus accrued but unpaid dividends to, but not including, the settlement date of the offer. For more details, see the Tender Offer Statement on Schedule TO (together with the exhibits and amendments thereto) filed by Abbott with the Securities and Exchange Commission on July 17, 2017.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Alere Inc.